191 related articles for article (PubMed ID: 23112250)
1. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250
[TBL] [Abstract][Full Text] [Related]
2. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.
Madhunapantula SV; Desai D; Sharma A; Huh SJ; Amin S; Robertson GP
Mol Cancer Ther; 2008 May; 7(5):1297-308. PubMed ID: 18483317
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Gowda R; Sharma A; Robertson GP
Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
[TBL] [Abstract][Full Text] [Related]
5. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.
Sharma A; Sharma AK; Madhunapantula SV; Desai D; Huh SJ; Mosca P; Amin S; Robertson GP
Clin Cancer Res; 2009 Mar; 15(5):1674-85. PubMed ID: 19208796
[TBL] [Abstract][Full Text] [Related]
6. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
Xia S; Zhao Y; Yu S; Zhang M
Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
[TBL] [Abstract][Full Text] [Related]
7. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.
Desai D; Kaushal N; Gandhi UH; Arner RJ; D'Souza C; Chen G; Vunta H; El-Bayoumy K; Amin S; Prabhu KS
Chem Biol Interact; 2010 Dec; 188(3):446-56. PubMed ID: 20883674
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Uddin S; Ahmed M; Hussain A; Assad L; Al-Dayel F; Bavi P; Al-Kuraya KS; Munkarah A
Int J Cancer; 2010 Jan; 126(2):382-94. PubMed ID: 19621391
[TBL] [Abstract][Full Text] [Related]
10. Melanoma prevention using topical PBISe.
Chung CY; Madhunapantula SV; Desai D; Amin S; Robertson GP
Cancer Prev Res (Phila); 2011 Jun; 4(6):935-48. PubMed ID: 21367959
[TBL] [Abstract][Full Text] [Related]
11. From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Zhong B; Cai X; Chennamaneni S; Yi X; Liu L; Pink JJ; Dowlati A; Xu Y; Zhou A; Su B
Eur J Med Chem; 2012 Jan; 47(1):432-444. PubMed ID: 22119125
[TBL] [Abstract][Full Text] [Related]
12. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.
Liu B; Wen JK; Li BH; Fang XM; Wang JJ; Zhang YP; Shi CJ; Zhang DQ; Han M
Cell Death Dis; 2011 Jul; 2(7):e185. PubMed ID: 21796157
[TBL] [Abstract][Full Text] [Related]
14. Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.
Lu JJ; Fu L; Tang Z; Zhang C; Qin L; Wang J; Yu Z; Shi D; Xiao X; Xie F; Huang W; Deng W
Oncotarget; 2016 Jan; 7(3):2985-3001. PubMed ID: 26672764
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
16. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
17. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
[TBL] [Abstract][Full Text] [Related]
18. In vitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320 cells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibition.
Balachandran C; Emi N; Arun Y; Yamamoto N; Duraipandiyan V; Inaguma Y; Okamoto A; Ignacimuthu S; Al-Dhabi NA; Perumal PT
Chem Biol Interact; 2016 Apr; 249():23-35. PubMed ID: 26915975
[TBL] [Abstract][Full Text] [Related]
19. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling.
Liu L; Kritsanida M; Magiatis P; Gaboriaud N; Wang Y; Wu J; Buettner R; Yang F; Nam S; Skaltsounis L; Jove R
Cancer Biol Ther; 2012 Nov; 13(13):1255-61. PubMed ID: 22895078
[TBL] [Abstract][Full Text] [Related]
20. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
